echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > AbbVie has teamed up with Rubin, India, for $1 billion to develop the first MALT-1 inhibitor to treat a series of blood systems:

    AbbVie has teamed up with Rubin, India, for $1 billion to develop the first MALT-1 inhibitor to treat a series of blood systems:

    • Last Update: 2021-02-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    AbbVie, the US biotech giant, recently teamed up with Lupin, the Indian pharmaceutical giant, to discover and develop a new class of oncology drugs to treat malignant tumors in the blood system.
    according to a statement released, Rubin has granted AbbVie exclusive rights to the development and commercialization of Rubin's first-in-class MALT1 (mucosal-related lymphoma congenital protein 1) inhibitor project. MALT-1 is a protein involved in the activity of T-cells and B-cell lymphocytes, and AbbVie plans to develop multiple inhibitors in the MALT1 inhibitor program for a range of hematological cancers, many of which are effective treatment options.
    under the terms of the agreement, AbbVie will pay Rubin a $30 million advance to obtain exclusive authorization for the Rubin MALT-1 inhibitor program. After successfully completing the regulatory, development and commercialization milestones, Rubin will be eligible for milestone payments totalling up to $947 million. In addition, Rubin is eligible for a two-figure royalty for future sales of products born out of the partnership, and Rubin retains commercial rights to the project in India.
    Rubin's MALT1 program is exploring a new way to treat incurable cancers," said Tom Hudson, vice president of drug discovery at AbbVie, a pharmaceutical company. AbbVie is committed to bringing advanced treatment options to patients. We look forward to working with Rubin's discovery program to bring new hope to patients. Dr
    Raj Kamboj, President of Rubin New Drug Discovery and Development (NDDD), said, "We are pleased that our NDDD project has successfully brought India's first pharmaceutical innovation into the field. The MALT1 project is a pioneering drug discovery project, provided exclusively by Rubin at all stages, from discovery to development. We are proud that the Rubin team meets global drug research standards in terms of concept transformation, strategic direction, and unassailable execution.
    2010, the Rubin New Drug Discovery and Development (NDDD) team's vision is to use cutting-edge research to develop innovative therapies and bring them globally to address unseeded medical needs in multiple therapeutic areas. At present, NDDD has established highly differentiated and innovative new chemical solid pipelines in the fields of oncology, immunology and metabolic disorder therapy. (Bio Valley)
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.